FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082632189> ?p ?o ?g. }

• W2082632189 endingPage "67" @default.
• W2082632189 startingPage "61" @default.
• W2082632189 abstract "The safety and efficacy of gossypol continues to be controversial. The aim of this study was to evaluate gossypol as a contraceptive pill for men at doses lower than those previously prescribed and in men from various ethnic origin. A total of 151 men from Brazil, Nigeria, Kenya, and China were divided into two groups. Both groups received 15 mg gossypol/day for 12 or 16 weeks to reach spermatogenesis suppression. Subjects were then randomized to either 7.5 or 10 mg/day for 40 weeks. In addition, 51 men were enrolled as a control group. In all, 81 subjects attained spermatogenesis suppression. Only one man discontinued treatment because of tiredness. Potassium levels fluctuated within the normal range. FSH increased consistently. Testicular volume decreased, but after discontinuation, values returned to levels not statistically different from admission. Of 19 subjects on the 7.5 mg/day dose group, 12 recovered sperm counts >20 million/mL within 12 months of discontinuing gossypol. In the 10 mg/day group, sperm counts recovered in only 10 of 24 subjects. Eight of the 43 patients remained azoospermic 1 year after stopping gossypol. All men diagnosed with varicocele failed to reverse spermatogenesis suppression. Gossypol blood levels indicated that sperm suppression occurs independently of concentration, whereas spermatogenesis recovery appears to be concentration-dependent. Gossypol may become a medical alternative to surgical vasectomy when the delay in onset of infertility is acceptable. When taken for 1 year, gossypol causes no reduction in sexual desire or frequency of intercourse. The possibility of reversal, occurring in 51% of the men on this regimen within 1 year after stopping gossypol, is an advantage of this compound as compared with surgical sterilization in many parts of the world.The safety and efficacy of gossypol continues to be controversial. The aim of this study was to evaluate gossypol as a contraceptive pill for men at doses lower than those previously prescribed and in men from various ethnic origin. A total of 151 men from Brazil, Nigeria, Kenya, and China were divided into two groups. Both groups received 15 mg gossypol/day for 12 or 16 weeks to reach spermatogenesis suppression. Subjects were then randomized to either 7.5 or 10 mg/day for 40 weeks. In addition, 51 men were enrolled as a control group. In all, 81 subjects attained spermatogenesis suppression. Only 1 man discontinued treatment because of tiredness. Potassium levels fluctuated within the normal range. FSH increased consistently. Testicular volume decreased, but after discontinuation, values returned to levels not statistically different from admission. Of 19 subjects in the 7.5 mg/day dose group, 12 recovered sperm counts higher than 20 million/ml within 12 months of discontinuing gossypol. In the 10 mg/day group, sperm counts recovered in only 10 of 24 subjects. 8 of the 43 patients remained azoospermic 1 year after stopping gossypol. All men diagnosed with varicocele failed to reverse spermatogenesis suppression. Gossypol blood levels indicated that sperm suppression occurs independently of concentration, whereas spermatogenesis recovery appears to be concentration-dependent. Gossypol may become a medical alternative to surgical vasectomy when the delay in onset of infertility is acceptable. When taken for 1 year, gossypol causes no reduction in sexual desire or frequency of intercourse. The possibility of reversal, occurring in 51% of the men on this regimen within 1 year after stopping gossypol, is an advantage of this compound as compared with surgical sterilization in many parts of the world." @default.
• W2082632189 created "2016-06-24" @default.
• W2082632189 creator A5011581456 @default.
• W2082632189 creator A5028819799 @default.
• W2082632189 creator A5035317522 @default.
• W2082632189 creator A5054916751 @default.
• W2082632189 creator A5061166283 @default.
• W2082632189 creator A5063736893 @default.
• W2082632189 creator A5069322664 @default.
• W2082632189 creator A5075179757 @default.
• W2082632189 creator A5076827301 @default.
• W2082632189 creator A5083854812 @default.
• W2082632189 creator A5086311785 @default.
• W2082632189 creator A5087162967 @default.
• W2082632189 date "2000-01-01" @default.
• W2082632189 modified "2023-09-29" @default.
• W2082632189 title "Gossypol blood levels and inhibition of spermatogenesis in men taking gossypol as a contraceptive" @default.
• W2082632189 cites W1693551679 @default.
• W2082632189 cites W2032086163 @default.
• W2082632189 cites W2063656154 @default.
• W2082632189 cites W2070682562 @default.
• W2082632189 cites W2092073321 @default.
• W2082632189 cites W2096716992 @default.
• W2082632189 cites W2137249683 @default.
• W2082632189 cites W2262385041 @default.
• W2082632189 cites W2289982822 @default.
• W2082632189 cites W4236010482 @default.
• W2082632189 doi "https://doi.org/10.1016/s0010-7824(99)00117-1" @default.
• W2082632189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10745071" @default.
• W2082632189 hasPublicationYear "2000" @default.
• W2082632189 type Work @default.
• W2082632189 sameAs 2082632189 @default.
• W2082632189 citedByCount "68" @default.
• W2082632189 countsByYear W20826321892012 @default.
• W2082632189 countsByYear W20826321892014 @default.
• W2082632189 countsByYear W20826321892015 @default.
• W2082632189 countsByYear W20826321892016 @default.
• W2082632189 countsByYear W20826321892018 @default.
• W2082632189 countsByYear W20826321892020 @default.
• W2082632189 countsByYear W20826321892021 @default.
• W2082632189 countsByYear W20826321892023 @default.
• W2082632189 crossrefType "journal-article" @default.
• W2082632189 hasAuthorship W2082632189A5011581456 @default.
• W2082632189 hasAuthorship W2082632189A5028819799 @default.
• W2082632189 hasAuthorship W2082632189A5035317522 @default.
• W2082632189 hasAuthorship W2082632189A5054916751 @default.
• W2082632189 hasAuthorship W2082632189A5061166283 @default.
• W2082632189 hasAuthorship W2082632189A5063736893 @default.
• W2082632189 hasAuthorship W2082632189A5069322664 @default.
• W2082632189 hasAuthorship W2082632189A5075179757 @default.
• W2082632189 hasAuthorship W2082632189A5076827301 @default.
• W2082632189 hasAuthorship W2082632189A5083854812 @default.
• W2082632189 hasAuthorship W2082632189A5086311785 @default.
• W2082632189 hasAuthorship W2082632189A5087162967 @default.
• W2082632189 hasConcept C123765429 @default.
• W2082632189 hasConcept C126322002 @default.
• W2082632189 hasConcept C16685009 @default.
• W2082632189 hasConcept C2776653637 @default.
• W2082632189 hasConcept C2776761254 @default.
• W2082632189 hasConcept C2777688143 @default.
• W2082632189 hasConcept C2778715236 @default.
• W2082632189 hasConcept C2779076696 @default.
• W2082632189 hasConcept C2779234561 @default.
• W2082632189 hasConcept C2780099242 @default.
• W2082632189 hasConcept C2781087480 @default.
• W2082632189 hasConcept C2908647359 @default.
• W2082632189 hasConcept C29456083 @default.
• W2082632189 hasConcept C2986817661 @default.
• W2082632189 hasConcept C42407357 @default.
• W2082632189 hasConcept C54355233 @default.
• W2082632189 hasConcept C55493867 @default.
• W2082632189 hasConcept C71924100 @default.
• W2082632189 hasConcept C86803240 @default.
• W2082632189 hasConcept C99454951 @default.
• W2082632189 hasConceptScore W2082632189C123765429 @default.
• W2082632189 hasConceptScore W2082632189C126322002 @default.
• W2082632189 hasConceptScore W2082632189C16685009 @default.
• W2082632189 hasConceptScore W2082632189C2776653637 @default.
• W2082632189 hasConceptScore W2082632189C2776761254 @default.
• W2082632189 hasConceptScore W2082632189C2777688143 @default.
• W2082632189 hasConceptScore W2082632189C2778715236 @default.
• W2082632189 hasConceptScore W2082632189C2779076696 @default.
• W2082632189 hasConceptScore W2082632189C2779234561 @default.
• W2082632189 hasConceptScore W2082632189C2780099242 @default.
• W2082632189 hasConceptScore W2082632189C2781087480 @default.
• W2082632189 hasConceptScore W2082632189C2908647359 @default.
• W2082632189 hasConceptScore W2082632189C29456083 @default.
• W2082632189 hasConceptScore W2082632189C2986817661 @default.
• W2082632189 hasConceptScore W2082632189C42407357 @default.
• W2082632189 hasConceptScore W2082632189C54355233 @default.
• W2082632189 hasConceptScore W2082632189C55493867 @default.
• W2082632189 hasConceptScore W2082632189C71924100 @default.
• W2082632189 hasConceptScore W2082632189C86803240 @default.
• W2082632189 hasConceptScore W2082632189C99454951 @default.
• W2082632189 hasIssue "1" @default.
• W2082632189 hasLocation W20826321891 @default.
• W2082632189 hasLocation W20826321892 @default.
• W2082632189 hasOpenAccess W2082632189 @default.

• next